国际医药卫生导报2011，Vol.17Issue(11)：1343-1346,4.DOI:10.3760/cma.j.issn.1007-1245.2011.11.022
白蛋白结合型紫杉醇在乳腺癌新辅助化疗中的应用
The application of albumin-bound paclitaxel in neoadjuvant chemotherapy for breast cancer
廖富毅 1潘瑞琳 1杨劫 1叶国麟 1古卫权1
作者信息
- 1. 528000,佛山市第一人民医院胸外乳腺外科
- 折叠
摘要
Abstract
Objective To assess the efficacy and adverse reactions of albumin-bound paclitaxel combined with epirubicin and cyclophosphamide in neoadjuvant chemotherapy for patients with breast cancer. Methods 18 patients with breast cancer received neoadjuvant chemotherapy with albuminbound paclitaxel combined with epirubicin and cyclophosphamide for four cycles, and then underwent surgery. The efficay and adverse reactions were assessed. Results The pCR rate was 38.9% and the total effective rate ( cCR puls cPR ) was 88.9%. The major adverse reactions which all the patients could tolerate included bone marrow suppression, gastrointestinal tract reaction, and sensory neurotoxicity. No allergic response occurred. Conclusions The neoadjuvant chemotherapy with albumin-bound paclitaxel combined with epirubicin and cyclophosphamide for breast cancer is significantly effective, and has fewer adverse reactions and a good tolerance.关键词
乳腺肿瘤/新辅助化疗/白蛋白结合型紫杉醇Key words
Breast cancer/Neoadjuvant chemotherapy/Albumin-bound paclitaxel引用本文复制引用
廖富毅,潘瑞琳,杨劫,叶国麟,古卫权..白蛋白结合型紫杉醇在乳腺癌新辅助化疗中的应用[J].国际医药卫生导报,2011,17(11):1343-1346,4.
